TACTI-004 Phase III Study Discontinuation

Immutep Limited announced the discontinuation of the TACTI-004 Phase III study for first-line non-small cell lung cancer. The Independent Data Monitoring Committee recommended termination due to futility, based on interim analysis of safety and efficacy data. Enrolment has been halted, and the company will conduct an orderly wind-down of the study. CEO Marc Voigt expressed disappointment and surprise, stating a comprehensive review of the data is underway to determine next steps. The discontinuation is expected to extend the company's cash runway beyond Q2 CY2027. Immutep remains focused on advancing its pipeline, including eftilagimod alfa (efti), the drug being studied in TACTI-004. The company will provide an updated outlook on its financial runway and capital allocation priorities after completing operational assessments and data analysis. The TACTI-004 study evaluated efti in combination with KEYTRUDA and chemotherapy. Efti is an MHC Class II agonist being evaluated for various cancers.